Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Genesis Pharma SA is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are assigned to 2 distinct examiners, with BEANE, RANDALL L serving as the busiest examiner with 1 pending action. This split ensures that the applications are reviewed by different individuals at the USPTO.
Both of the matters are being prosecuted within 1 distinct art unit. This concentration suggests that the technology involved is highly specialized within the Biotechnology & Pharmaceuticals field. Having 2 distinct examiners in a single art unit allows the applicant to compare different examination styles while dealing with the same art unit standards.
The presence of those examiners for the 2 pending office actions provides a diversified approach to prosecution. However, the focus on 1 distinct art unit means that the applicant should look for consistent themes in the rejections across the matters. BEANE, RANDALL L manages 1 pending action, representing a significant portion of the current activity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624690 | COMBINATION | D' AMBROSIO, THEA | 55d |
| 18684454 | COMBINATION OF A NURR1 AGONIST WITH AT LEAST ONE OF AN ALDOSTERONE ANTAGONIST, AN INSULIN MODULATOR AND A SULFONYLUREA | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624690 | COMBINATION | D' AMBROSIO, THEA | 55d |
| 18684454 | COMBINATION OF A NURR1 AGONIST WITH AT LEAST ONE OF AN ALDOSTERONE ANTAGONIST, AN INSULIN MODULATOR AND A SULFONYLUREA | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684454 | COMBINATION OF A NURR1 AGONIST WITH AT LEAST ONE OF AN ALDOSTERONE ANTAGONIST, AN INSULIN MODULATOR AND A SULFONYLUREA | BEANE, RANDALL L | — | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 17624690 | COMBINATION | D' AMBROSIO, THEA | 1654 | §102§112Other | Non-Final OA | 55d | Pending | Jan 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial